Medyria Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4.33M
- Investors
-
6
Medyria General Information
Description
Developer of a physiology assessment device intended to advance the diagnosis and treatment of heart ischemia. The company offers a comprehensive system that assesses full cardiovascular function and detects early signs of ischemia, enabling healthcare professionals to intervene earlier and prevent progression to myocardial infarction.
Contact Information
Website
www.medyria.comCorporate Office
- Technoparkstrasse 2c
- 8406 Winterthur
- Switzerland
Corporate Office
- Technoparkstrasse 2c
- 8406 Winterthur
- Switzerland
Medyria Timeline
Medyria Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Later Stage VC | 24-Jul-2026 | $4.33M | Completed | Generating Revenue | ||
| 13. Secondary Transaction - Private | 01-Jun-2026 | Completed | Generating Revenue | |||
| 12. Accelerator/Incubator | 01-Jan-2026 | Completed | Generating Revenue | |||
| 11. Later Stage VC | 14-Jul-2025 | Completed | Generating Revenue | |||
| 10. Later Stage VC | 05-Dec-2023 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series B) | 22-Dec-2022 | Completed | Generating Revenue | |||
| 8. Grant | 05-Sep-2019 | Completed | Pre-Clinical Trials | |||
| 7. Later Stage VC | 31-Aug-2019 | Completed | Pre-Clinical Trials | |||
| 6. Later Stage VC (Series B) | 02-Feb-2018 | $3.86M | $7.26M | Completed | Pre-Clinical Trials | |
| 5. Early Stage VC (Series A) | 16-Dec-2016 | $1.12M | $3.4M | Completed | Pre-Clinical Trials |
Medyria Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| B Preferred | ||||||||
| B Preferred | ||||||||
| B Preferred | ||||||||
| A Preferred | 131,901 | $1.127560 | $39.46 | $39.46 | 1x | $39.46 | 28.35% | |
| A Preferred | 109,647 | $1.127560 | $33.83 | $33.83 | 1x | $33.83 | 23.57% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Medyria Comparisons
Industry
Financing
Details
Medyria Competitors (17)
One of Medyria’s 17 competitors is Elixir Medical, a Venture Capital-Backed company based in Milpitas, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Elixir Medical | Venture Capital-Backed | Milpitas, CA | ||||
| Biotronik | Corporate Backed or Acquired | Berlin, Germany | ||||
| Vascular Insights | Corporate Backed or Acquired | South Jordan, UT | ||||
| New View Medical | Venture Capital-Backed | Andover, MA | ||||
| CardioFocus | Venture Capital-Backed | Marlborough, MA |
Medyria Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Medyria Patents
Medyria Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4366611-A1 | Sensors catheter and signal processing for blood flow velocity assessment | Pending | 07-Jul-2021 | ||
| US-20240293033-A1 | Sensors catheter and signal processing for blood flow velocity assessment | Pending | 07-Jul-2021 | ||
| WO-2023280736-A1 | Sensors catheter and signal processing for blood flow velocity assessment | Inactive | 07-Jul-2021 | ||
| EP-3749175-A1 | Arrangement with catheter and sensor arrangement | Active | 05-Feb-2018 | ||
| EP-3749175-B1 | Arrangement with catheter and sensor arrangement | Active | 05-Feb-2018 | A61B5/6852 |
Medyria Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Medyria Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| MedTech Innovator | Accelerator/Incubator | |||
| Buenavista Equity Partners | Asset Manager | Minority | ||
| Buenavista Equity Partners Portugal | Asset Manager | Minority | ||
| EFI Lake Geneva Ventures | Venture Capital | Minority | ||
| Dragon's Den | SBIC |
Medyria FAQs
-
When was Medyria founded?
Medyria was founded in 2012.
-
Where is Medyria headquartered?
Medyria is headquartered in Winterthur, Switzerland.
-
What is the size of Medyria?
Medyria has 9 total employees.
-
What industry is Medyria in?
Medyria’s primary industry is Monitoring Equipment.
-
Is Medyria a private or public company?
Medyria is a Private company.
-
What is Medyria’s current revenue?
The current revenue for Medyria is .
-
How much funding has Medyria raised over time?
Medyria has raised $20.5M.
-
Who are Medyria’s investors?
MedTech Innovator, Buenavista Equity Partners, Buenavista Equity Partners Portugal, EFI Lake Geneva Ventures, and Dragon's Den are 5 of 6 investors who have invested in Medyria.
-
Who are Medyria’s competitors?
Elixir Medical, Biotronik, Vascular Insights, New View Medical, and CardioFocus are some of the 17 competitors of Medyria.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
